Sumitomo

For profit

Also known as: SUMITOMO PHARMA AM | Sumitomo Pharmaceuticals America | Sumitomo Pharmaceutical (Suzhou) Co., Ltd. | Sumitomo Pharma Co., Ltd. | Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

Apr 1, 2008

First marketed drug

Nov 8, 2013

Last known activity

Dec 31, 2024

Acquired by Sumitomo Dainippon on Jan 1, 2005

Timeline

1980s

Jan 1, 1986
Sumitomo— Founded

2000s

Jan 1, 2005
Sumitomo Dainippon— Acquired By

2010s

Nov 8, 2013
eslicarbazepine acetate— Marketing Organization

2020s

Dec 18, 2020
relugolix— NDA Secondary Org
Apr 2, 2023
Roivant Sciences, Inc.— Acquired

Drugs by trial phase (44 distinct, 55 trials)

Phase 4 (10 own, 1 via acquisition)

Phase 3 (6 own, 1 via acquisition)

Phase 2 (5 own, 9 via acquisition)

Phase 1 (5 own, 7 via acquisition)

Indications

Studied for

Marketed drugs (5)

Subsidiaries (1 direct, 5 total across the full acquisition tree)

Recent trials (24)

NCT06636162CollaboratorEarly Phase 1Dec 31, 2024
NCT06463457CollaboratorPhase 2Nov 30, 2024
NCT06330805CollaboratorPhase 2Aug 12, 2024
NCT06460064Lead sponsorPhase 1Jun 26, 2024
NCT06482268CollaboratorPhase 1Jun 1, 2024
NCT05593029CollaboratorPhase 2/Phase 3Nov 9, 2022
NCT05435729Lead sponsorPhase 1May 31, 2022
NCT05366868CollaboratorPhase 4May 26, 2022
NCT05359081Lead sponsorPhase 3May 16, 2022
NCT05213143Lead sponsorPhase 4Jan 31, 2022
NCT05011669Lead sponsorPhase 4Aug 16, 2021
NCT04518345CollaboratorPhase 1/Phase 2Nov 5, 2020
NCT04383691Lead sponsorPhase 3Jun 30, 2020
NCT04239950CollaboratorPhase 3Jan 20, 2020
NCT03784222Lead sponsorPhase 4Jan 22, 2019

Details

Founded: Ehime, JP Jan 1, 1986
Last known activity: Dec 31, 2024